Personalized Thera(g)nostic Approach in Patients with Pheochromocytoma and Paraganglioma: 131I-mIBG and/or Peptide Receptor Radionuclide Therapy

被引：0
|
作者：
Svirydenka, H. [1 ]
Nilica, B. [1 ]
Mair, C. [1 ]
Rossetti, L. [1 ]
Kroiss, A. [1 ]
Di Santo, G. [1 ]
Buxbaum, S. [1 ]
Decristoforo, C. [1 ]
Uprimny, C. [1 ]
Gabriel, M. [1 ]
Virgolini, I. [1 ]
机构：
[1] Univ Klin Nukl Med, Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-563
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [21] Peptide receptor radionuclide therapy in malignant pheochromocytoma and paraganglioma treatment
    Nematyazar, J.
    Vatankulu, B.
    Demirci, E.
    Asa, S.
    Ocak, M.
    Uslu
    Kabasakal, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S422 - S422
  • [22] Semiquantitative 131I-MIBG Scintigraphy Predicts Intraoperative Blood Pressure Fluctuation in Patients Receiving Surgery for Pheochromocytoma and Paraganglioma
    Ma, Jiangyu
    Ji, Heyu
    Wang, Chu
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [23] Long-term efficacy of 131I-MIBG therapy in malignant paraganglioma and phaeochromocytoma
    Castellani, M. R.
    Luksch, R.
    Seregni, E.
    Maccauro, M.
    Chiesa, C.
    Aliberti, G.
    Orunesu, E.
    Bombardieri, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S218 - S218
  • [24] Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma
    Lu, Yang
    Xu, Guofan
    Jimenez, Camilo
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (04) : 320 - 323
  • [25] Sequelae and survivorship in patients treated with 131I-MIBG therapy
    W C C Sze
    A B Grossman
    I Goddard
    D Amendra
    S C C Shieh
    P N Plowman
    W M Drake
    S A Akker
    M R Druce
    British Journal of Cancer, 2013, 109 : 565 - 572
  • [26] 131I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy
    Castellani, M. R.
    Seghezzi, S.
    Chiesa, C.
    Aliberti, G. L.
    Maccauro, M.
    Seregni, E.
    Orunesu, E.
    Luksch, R.
    Bombardieri, E.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 100 - 113
  • [27] Sequelae and survivorship in patients treated with 131I-MIBG therapy
    Sze, W. C. C.
    Grossman, A. B.
    Goddard, I.
    Amendra, D.
    Shieh, S. C. C.
    Plowman, P. N.
    Drake, W. M.
    Akker, S. A.
    Druce, M. R.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 565 - 572
  • [28] Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
    Kong, Grace
    Grozinsky-Glasberg, Simona
    Hofman, Michael S.
    Callahan, Jason
    Meirovitz, Amichay
    Maimon, Ofra
    Pattison, David A.
    Gross, David J.
    Hicks, Rodney J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (09): : 3278 - 3287
  • [29] 131-METAIODOBENZYLGUANIDINE (131 MIBG) THERAPY FOR PATIENTS WITH MALIGNANT PHEOCHROMOCYTOMA AND PARAGANGLIOMA: THE ISRAELI EXPERIENCE
    Shilkrut, M.
    Bar-Deroma, R.
    Bar Sela, G.
    Kuten, A.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S303 - S303
  • [30] Clinical Dosimetry Tool Implementation of I-131 MIBG Therapy for Pheochromocytoma and Paraganglioma
    Franco, R. Perez
    Pugachev, A.
    MEDICAL PHYSICS, 2020, 47 (06) : E519 - E519
12345